Biote Corp (BTMD) Stock Price, Quote & News

Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method...

Industry: Medical Care Facilities

Sector: Healthcare

Phone: 844 604 1246

Website: www.biote.com

Address:

1875 W. Walnut Hill Ln #100, Irving, United States

Cramerican1 Jun. 3 at 5:49 PM

$BTMD just needs some volume

0 · Reply

2sexyBiatch May. 30 at 5:48 PM

$BTMD another sleeper $KIDZ

0 · Reply

Rasto2020 May. 9 at 12:00 PM

$BTMD sorry for another post, it touched EMa yesterday on the nose. It needs to cross to confirm it or it might pullback a little

1 · Reply

Rasto2020 May. 9 at 11:58 AM

$BTMD it crossed above downtrend on weekly which is amazing . We still have today so we should see, but on a big watch

0 · Reply

Rasto2020 May. 9 at 11:54 AM

$BTMD very interesting

0 · Reply

sillysajji May. 8 at 4:39 PM

$BTMD nothing happening after such a nice earnings. I don't understand why

0 · Reply

Cramerican1 May. 8 at 11:17 AM

$BTMD looking for $4 test today

0 · Reply

Wrenboy May. 1 at 3:32 PM

$BTMD wtf happened earlier this morning, did ttvey just take out all the stop losses for small gainer? Weird.$1.80 dip

0 · Reply

AZOZ Apr. 11 at 11:49 AM

$OMI $BTMD Insider's love it right now!

0 · Reply

tilance Apr. 8 at 3:15 PM

$BTMD opened a position here today.

0 · Reply

Biote Names Rich Barrera to Board of Directors

May 11, 2025, 2:55 AM EDT - 5 weeks ago

biote Corp. (BTMD) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 5 weeks ago

Biote Reports First Quarter 2025 Financial Results

Apr 23, 2025, 4:05 PM EDT - 7 weeks ago

Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

Mar 18, 2025, 5:30 PM EDT - 3 months ago

Biote Announces Purchase of Shares by Directors and CEO

Mar 12, 2025, 9:33 PM EDT - 3 months ago

biote Corp. (BTMD) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:05 PM EDT - 3 months ago

Biote Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:05 PM EST - 3 months ago

Biote Schedules Fourth Quarter and Full Year 2024 Financial Results Release and Conference Call

Jan 30, 2025, 4:10 PM EST - 4 months ago

Biote Announces CEO Retirement and Succession Plan

Nov 13, 2024, 2:56 AM EST - 7 months ago

biote Corp. (BTMD) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 7 months ago

Biote Reports Third Quarter 2024 Financial Results

Oct 29, 2024, 4:05 PM EDT - 8 months ago

Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call

Aug 10, 2024, 2:42 PM EDT - 11 months ago

biote Corp. (BTMD) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 11 months ago

Biote Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 4:05 PM EDT - 11 months ago

Biote Schedules Second Quarter 2024 Financial Results Release and Conference Call

Jun 20, 2024, 4:45 PM EDT - 1 year ago

Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares

May 9, 2024, 3:58 AM EDT - 1 year ago

biote Corp. (BTMD) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

Biote Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:05 PM EDT - 1 year ago

Biote Announces Definitive Settlement with Founder

Apr 23, 2024, 4:05 PM EDT - 1 year ago

Biote Schedules First Quarter 2024 Financial Results Release and Conference Call

Mar 15, 2024, 2:33 PM EDT - 1 year ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN DARE

Mar 12, 2024, 7:45 PM EDT - 1 year ago

biote Corp. (BTMD) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Biote Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 1 year ago

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

Feb 20, 2024, 4:05 PM EST - 1 year ago

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder's Shares

Jan 25, 2024, 4:05 PM EST - 1 year ago

Biote Announces $20 Million Share Repurchase Authorization

Jan 17, 2024, 4:05 PM EST - 1 year ago

Biote to Purchase Asteria Health

Jan 17, 2024, 4:05 PM EST - 1 year ago

Biote Provides Preliminary 2023 Results and Initial 2024 Guidance

Jan 11, 2024, 4:05 PM EST - 1 year ago

Biote Names Robert Peterson as Chief Financial Officer

Nov 29, 2023, 11:34 PM EST - 1 year ago

biote Should Keep Delivering Strong Growth

Nov 7, 2023, 4:45 PM EST - 1 year ago

Biote Reports Third Quarter 2023 Financial Results

Oct 24, 2023, 8:30 AM EDT - 1 year ago

Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Biote Reports Second Quarter 2023 Financial Results

Jul 27, 2023, 8:30 AM EDT - 2 years ago

Biote Schedules Second Quarter 2023 Financial Results Release and Conference Call

Jun 22, 2023, 7:00 AM EDT - 2 years ago

Biote Formalizes Commitment to Men's Hormone Health With Launch of New Men's Health Division

Jun 8, 2023, 6:05 PM EDT - 2 years ago

Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

Jun 5, 2023, 7:48 AM EDT - 2 years ago

Biote Announces Pricing of Secondary Offering of Common Stock

May 31, 2023, 8:30 AM EDT - 2 years ago

Biote to Participate at Upcoming Investor Conferences

May 30, 2023, 8:30 AM EDT - 2 years ago

Biote Appoints Mary J. Puncochar as Chief Commercial Officer

May 9, 2023, 5:21 PM EDT - 2 years ago

Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

May 9, 2023, 5:21 PM EDT - 2 years ago

Biote Reports First Quarter 2023 Financial Results

Apr 26, 2023, 8:30 AM EDT - 2 years ago

Biote Schedules First Quarter 2023 Financial Results Release and Conference Call

Apr 10, 2023, 8:30 AM EDT - 2 years ago

Biote Names John Denne as General Manager, Men's Health Division

Mar 28, 2023, 4:15 PM EDT - 2 years ago

Biote Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 27, 2023, 9:00 AM EDT - 2 years ago

Study: Testosterone Pellet Therapy Significantly Improves Bone Density in Male Patient Case Report

Mar 2, 2023, 8:00 AM EST - 2 years ago

Biote to Present at 35th Annual Roth Conference

Feb 9, 2023, 4:15 PM EST - 2 years ago

Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call

Jan 9, 2023, 5:30 PM EST - 2 years ago

Biote Announces Closing of Secondary Offering of 8,500,000 Shares of Common Stock Including Full Exercise of the Underwriters' Over-Allotment Option

Nov 10, 2022, 8:30 AM EST - 2 years ago

Biote to Present at Jefferies London Healthcare Conference

Nov 8, 2022, 4:15 PM EST - 2 years ago

Biote Reports Third Quarter Financial Results

Cramerican1 Jun. 3 at 5:49 PM

$BTMD just needs some volume

0 · Reply

2sexyBiatch May. 30 at 5:48 PM

$BTMD another sleeper $KIDZ

0 · Reply

Rasto2020 May. 9 at 12:00 PM

$BTMD sorry for another post, it touched EMa yesterday on the nose. It needs to cross to confirm it or it might pullback a little

1 · Reply

Rasto2020 May. 9 at 11:58 AM

$BTMD it crossed above downtrend on weekly which is amazing . We still have today so we should see, but on a big watch

0 · Reply

Rasto2020 May. 9 at 11:54 AM

$BTMD very interesting

0 · Reply

sillysajji May. 8 at 4:39 PM

$BTMD nothing happening after such a nice earnings. I don't understand why

0 · Reply

Cramerican1 May. 8 at 11:17 AM

$BTMD looking for $4 test today

0 · Reply

Wrenboy May. 1 at 3:32 PM

$BTMD wtf happened earlier this morning, did ttvey just take out all the stop losses for small gainer? Weird.$1.80 dip

0 · Reply

AZOZ Apr. 11 at 11:49 AM

$OMI $BTMD Insider's love it right now!

0 · Reply

tilance Apr. 8 at 3:15 PM

$BTMD opened a position here today.

0 · Reply

Tyranic Apr. 4 at 12:23 AM

$BTMD wanna $$$ … short the fk out of this. NOT FINANCIAL ADVICE

1 · Reply

NVDAMillionaire Mar. 29 at 10:51 PM

$BTMD Bullish on BTMD's hormone optimization play. Their practitioner network is expanding fast. QuickStart program looks promising for scaling. Might initiate a small position to track their growth trajectory. Regulatory risks are real but management seems capable. Great writeup: https://beyondspx.com/article/the-growing-opportunity-behind-biote-corp-btmd

0 · Reply

redrussian Mar. 19 at 1:44 PM

$PSEC 4.28 $MKZR 1.85 $BTMD 3.87

0 · Reply

CEOBuysDisclosures Mar. 19 at 1:50 AM

$BTMD CEO purchased 37,595 shares at $3.87 for a total of $145,493. Christensen Bret now owns 37,595 shares. https://ceo-buys.com

0 · Reply

Disrupter Mar. 18 at 2:54 AM

$BTMD whats the cash position

0 · Reply

ajmrtxl Mar. 14 at 2:42 PM

$BTMD 's latest data on Squeezefinder

0 · Reply

Fib7867 Mar. 13 at 11:07 PM

#myBTMDanalysis $BTMD

0 · Reply

CrayP Mar. 13 at 2:36 PM

$BTMD Raally cheap down here... market didn't believe consensus which is why it had traded well down in advance. Now at 1.5X Sales and 5X EBITDA even after factoring the settlement liability with growth reaccelerating in 2H. At Roth Conf next week...

1 · Reply

JarvisFlow Mar. 13 at 1:38 PM

Craig-Hallum has adjusted their stance on Biote ( $BTMD ), setting the rating to Buy with a target price of 12 → 8.

0 · Reply

DonCorleone77 Mar. 12 at 8:29 PM

$BTMD Biote sees FY25 revenue $202M-$208M, consensus $226.16M Sees FY25 adjusted EBITDA $59M-$64M.

0 · Reply

DonCorleone77 Mar. 12 at 8:29 PM

$BTMD Biote reports Q4 EPS 10c vs 18c last year Reports Q4 revenue $49.8M, consensus $51.2M. "In 2024 Biote strengthened its capabilities to provide the next level of individualized and evidence-based healthcare," said Bob Peterson, Biote Chief Financial Officer. "Full year 2024 revenue increased 6.4% compared to 2023 and, with continued efficiencies from the vertical integration of our 503B manufacturing facility, gross profit margin also improved. Even as fourth quarter procedure volume was impacted due to the transition to upgraded clinical decision support software throughout our network, fourth quarter revenue increased 9.0%. We are continuing to work closely with our practitioners and are offering additional training on our enhanced software. We ended the year in a strong financial position, with $39.3 million in cash and cash equivalents on our balance sheet."

0 · Reply

Cramerican1 Mar. 12 at 8:08 PM

$BTMD massive beat

1 · Reply

Market Cap	206.80M
Revenue (ttm)	197.19M
Net Income (ttm)	3.16M
EPS (ttm)	N/A
PE Ratio	6.08
Forward PE	12.34
Profit Margin	1.60%
Debt to Equity Ratio	-1.25

Volume	97,100
Avg Vol	159,166
Day's Range	N/A - N/A
Shares Out	54.71M
Stochastic %K	67%
Beta	1.16
Analysts	Strong Sell
Price Target	$6.66